Mounjaro vs Zepbound: Cost, Coverage & Which to Choose (2026)

Last updated: May 28, 2026

Mounjaro and Zepbound are the same drug — tirzepatide — from the same manufacturer — Eli Lilly — at the same dose strengths. They are pharmacologically identical. But they carry different brand names, different FDA-approved indications, and different pricing programs. The result: the cheaper option depends entirely on your insurance situation, and getting it wrong can cost you over $1,000 per year on the exact same medication.

This is the definitive 2026 Mounjaro vs Zepbound cost comparison: real retail prices, savings card math (covered and uncovered tracks), self-pay through LillyDirect and TrumpRx, compounded tirzepatide alternatives, insurance coverage rates, and a clear decision framework that names the cheapest path for each scenario.

Mounjaro vs Zepbound: What's the Difference? (Quick Answer)

Both contain tirzepatide. Same molecule, same Eli Lilly manufacturing, same available dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The pharmacy receives identical drug product. The clinical effect is identical.

The differences are in the labeling and the price-and-coverage ecosystem:

• Mounjaro is FDA-approved for type 2 diabetes and obstructive sleep apnea. Weight loss is a known benefit but not the labeled indication.
• Zepbound is FDA-approved specifically for chronic weight management and obstructive sleep apnea.
• Mounjaro list price is roughly $1,070/month; Zepbound list price is roughly $1,086/month. Retail pricing is within $20 of each other.
• Mounjaro has ~82% commercial insurance coverage (because it's a diabetes drug, broadly covered). Zepbound has only 30–40% coverage for weight management.
• Mounjaro is no longer on LillyDirect self-pay; Zepbound is ($299–$449 tiered by dose).
• Lilly Cares Foundation PAP covers Zepbound (free medication for income-qualified uninsured patients); Lilly Cares does NOT cover Mounjaro.
• Medicare GLP-1 Bridge covers Zepbound (KwikPen formulation only) at $50/month from July 2026; Mounjaro is not in the Bridge.

Practical answer: Mounjaro is cheaper if you have commercial insurance with diabetes coverage. Zepbound is cheaper if you're paying cash, qualify for Lilly Cares, or qualify for the Medicare Bridge. Same drug, different access paths.

Mounjaro vs Zepbound Cost Comparison 2026

Side-by-side pricing across every realistic acquisition path. All figures verified May 28, 2026.

Where to Get Mounjaro and Zepbound at the Lowest Cost

LillyDirect (Eli Lilly Direct-to-Consumer)

Eli Lilly sells Zepbound vials directly to consumers via LillyDirect's Self Pay Pharmacy program at $299–$449/month depending on dose strength. Free home delivery. No insurance required. As of May 2026, Mounjaro is no longer offered through LillyDirect's self-pay channel — Lilly has consolidated Mounjaro distribution through pharmacy and commercial-insurance pathways instead. This is one of the most consequential cost differences in 2026: cash-paying patients can buy Zepbound directly from Lilly but not Mounjaro.

Telehealth Providers

National telehealth platforms now prescribe both brand-name Zepbound and compounded tirzepatide, with self-pay pricing that often beats retail and savings-card net prices. Current verified options:

• Oak — compounded tirzepatide at $199/month flat across all dose strengths. No membership fee, no consultation fee, no shipping fee.
• Hims — Zepbound from $299/month with the standard $39 first-month / $149/month renewal Hims Body membership.
• Liv Body — compounded tirzepatide at $279/month all-in. Includes Care Coach health-coaching layer, no separate membership fee.
• FeelGood — compounded injections from $149/month all-in. Compounded tablets also available from $249/month. HSA/FSA eligible.

To compare every active telehealth provider with the full fee breakdown (membership, consultation, shipping), use our comparison tool. Sorted by total monthly cost with the verified-provider snapshot for every listed brand — we verify each platform's business registration and licensed pharmacy fulfillment before listing.

Pharmacy Savings Cards and Coupons

Eli Lilly's Mounjaro and Zepbound Savings Cards are the headline copay reducers. Both drop the commercial-insurance copay to $25/month when your plan covers the drug. When your plan does NOT cover the drug, both cards offer a separate "uncovered" rebate: up to $499 off Mounjaro (net ~$571/month) and up to $650 off Zepbound (net ~$436/month). Both cards expire December 31, 2026 with annual renewal. Full mechanics in our GLP-1 savings cards guide.

Compounded Tirzepatide Alternatives

Licensed compounding pharmacies dispense compounded tirzepatide under the FDA's drug-shortage provisions. The active ingredient is the same as brand Mounjaro and Zepbound; the regulatory category is different (compounded products are not FDA-approved the way brand products are). Verified telehealth providers like Oak run compounded tirzepatide at $199/month flat, dramatically undercutting both Mounjaro and Zepbound brand pricing. Trade-off: compounded products have a weaker regulatory wrapper, the FDA has issued warnings about some compounded semaglutide products, and quality control varies by pharmacy. Always verify provider legitimacy through our provider check process before signing up.

GoodRx and Discount Cards

GoodRx coupons typically don't meaningfully discount brand-name Mounjaro or Zepbound because both are still under patent and Lilly tightly controls retail pricing through PBM contracts. Reasonable cash-discount cards may shave $30–$80/month off retail, but the discounted price still lands well above LillyDirect (for Zepbound) or TrumpRx (for either drug). For most patients, the savings-card / direct-self-pay / compounded paths beat coupon-card-discounted retail.

Insurance Coverage: Mounjaro vs Zepbound

This is the single biggest cost-determining factor for most patients, and it's where the brands diverge sharply despite being the same molecule.

Commercial Insurance

Mounjaro: approximately 82% of commercial plans cover Mounjaro for type 2 diabetes. Diabetes is a mandated coverage category under most employer plan designs, and tirzepatide is a tier 3 or tier 4 specialty drug on the typical diabetes formulary. With the Mounjaro Savings Card layered on top of commercial coverage, your monthly copay typically lands at $25.

Zepbound: only 30–40% of commercial plans cover Zepbound for weight management. Weight-loss drugs are widely excluded from employer plan designs — many plans carry an explicit "weight management" exclusion that disqualifies Zepbound regardless of BMI or comorbidity. When a plan does cover Zepbound, the savings card brings the copay to $25/month. When it doesn't, the savings card's "up to $650 off" rebate lands you at a net ~$436/month — meaningfully higher than LillyDirect's $299–$449 self-pay tier or compounded tirzepatide.

Off-Label Strategy: Mounjaro Prescribed for Weight Loss

Some prescribers will write Mounjaro off-label for patients seeking weight loss but who also have a documented diabetes risk profile (pre-diabetes, metabolic syndrome). The strategy attempts to get diabetes-formulary coverage on what is effectively a weight-management prescription. This works for some plans and fails for others. Most insurers cross-check the diagnosis on the prior-authorization form against the drug indication, and some PBMs flag Mounjaro prescriptions written for patients without a confirmed type 2 diabetes ICD-10 code. Discuss the strategy honestly with your prescriber — it's a real path for some patients but not universally available.

Medicare and Medicaid

Medicare Part D: Mounjaro is typically covered for type 2 diabetes on most Part D formularies, usually on a higher specialty tier ($75–$250 monthly copays depending on plan and drug stage). Zepbound for weight management has historically been excluded from Part D under the longstanding rule that weight-loss drugs aren't a Medicare benefit. That changes (partially and temporarily) on July 1, 2026 when the Medicare GLP-1 Bridge Program launches, covering Zepbound KwikPen (only) at $50/month for qualifying beneficiaries. Mounjaro is not in the Bridge.

Medicaid: Coverage of Mounjaro for diabetes is standard across all 50 states. Coverage of Zepbound for weight management varies enormously — only 13 states plus DC cover weight-loss GLP-1s under Medicaid as of 2026. See our state-by-state Medicaid coverage guide for specifics.

Prior Authorization (Both Drugs)

Most commercial and Medicare plans that cover Mounjaro or Zepbound require prior authorization before the pharmacy can dispense. The PA process typically requires: confirmed diagnosis (ICD-10 code), BMI documentation (for Zepbound or off-label Mounjaro for weight loss), prior weight-loss attempts documented, and prescriber rationale. Approval timelines run 1–3 weeks. Denials happen frequently — appeal success rates are 44–80% with proper documentation of medical necessity.

Mounjaro vs Zepbound: Dosing and How It Affects Cost

Both Mounjaro and Zepbound use the same dose escalation schedule: 2.5 mg starter (typically 4 weeks), then step up to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a 15 mg maintenance maximum. Most patients take 8–20 weeks to reach a steady-state maintenance dose, depending on tolerability.

Cost Implications of the Dose Ladder

Pricing programs vary by how they treat the dose ladder:

• LillyDirect (Zepbound only) charges by dose tier: $299/month for the 2.5 mg starter, ~$399 for 5 mg, ~$449 for 7.5 mg and higher. Higher maintenance doses cost meaningfully more than the starter.
• TrumpRx charges a flat monthly fee regardless of dose: $350 for Mounjaro, $299 for Zepbound. Your monthly cost doesn't change as you escalate.
• Oak (compounded tirzepatide) charges $199/month flat across all dose strengths. The cheapest path at maintenance dose by a wide margin.
• Savings card ($25/month copay) holds steady regardless of dose when your plan covers the drug. The "up to $X off" non-covered track also doesn't scale with dose.

How Long You Stay on Each Dose Matters

If your prescriber escalates you to 7.5 mg and you stay there 6+ months before stepping up to maintenance, you'll spend more on a tiered program (LillyDirect) than on a flat program (TrumpRx, Oak). For patients on long-term maintenance, the flat-rate programs typically work out cheaper over a year. For patients in the early titration period (first 2–4 months at lower doses), the LillyDirect $299 starter is competitive.

For a full Mounjaro per-dose cost analysis, see our Mounjaro cost at every dose article. For Zepbound specifically, see Zepbound cost without insurance.

"Oral Zepbound": What's Actually Available

Searches for "oral Zepbound" are common, so it's worth being precise: there is no oral Zepbound. Zepbound is brand tirzepatide and is only sold as an injectable (KwikPen, single-dose pen, single-dose vial). Eli Lilly has not announced an oral tirzepatide product as of May 2026.

The oral GLP-1 options that exist in 2026 are different molecules, not oral versions of Zepbound:

• Foundayo (orforglipron) — Eli Lilly's oral weight-loss GLP-1, FDA-approved April 1, 2026. Not tirzepatide; orforglipron is a non-peptide small molecule. First weight-loss GLP-1 pill with no food or water restrictions. Starts at $149/month via LillyDirect.
• Wegovy tablet (oral semaglutide) — Novo Nordisk's oral weight-loss GLP-1, FDA-approved January 2026. Not tirzepatide; semaglutide is a different molecule. Must be taken on an empty stomach. Starts at $149/month via NovoCare.
• Rybelsus (oral semaglutide 3/7/14 mg) — Novo Nordisk's diabetes-only oral semaglutide. Lower doses than Wegovy tablet. Sometimes prescribed off-label for weight loss but insurance rarely covers it for that indication.

If you want a tirzepatide pill specifically, the answer is: it doesn't exist yet. If you want an oral weight-loss GLP-1, see our oral GLP-1 cost comparison for the full Wegovy-pill-vs-Foundayo head-to-head.

Mounjaro vs Zepbound vs Ozempic: Quick Cost Comparison

If you're comparing across the three most-searched GLP-1 brands, here's the simplified pricing picture in 2026:

If you're choosing between Mounjaro and Ozempic for diabetes: both are well-covered commercially, both land at $25/month with savings card. Clinically, tirzepatide (Mounjaro) tends to produce greater weight loss as a side effect than semaglutide (Ozempic) in head-to-head trials. For pure diabetes management with insurance, either works.

If you're choosing between Zepbound and Ozempic and paying cash: Ozempic isn't a weight-loss drug under its FDA label, but for diabetes patients self-paying via TrumpRx or compounded semaglutide telehealth providers, Ozempic-equivalent pricing can land below Zepbound's $299. Compounded semaglutide through providers like Oak runs $133/month. See Ozempic cost without insurance for the full breakdown.

Which Should You Choose? Decision Framework

Five common scenarios and the cheapest realistic path for each:

1. You have type 2 diabetes and commercial insurance. Choose Mounjaro. ~82% coverage rate plus savings card = $25/month copay. Zepbound's coverage rate for weight management is too low to compete here, and your diabetes diagnosis steers you onto Mounjaro's labeled indication.
2. You want weight loss, you have commercial insurance, and your plan covers Zepbound. Choose Zepbound. Savings card = $25/month copay. Same as Mounjaro for diabetes patients — if you have coverage, the savings card is the cheapest route.
3. You want weight loss, commercial insurance, plan does NOT cover Zepbound. Compare carefully. Savings card non-covered track lands at ~$436/month. LillyDirect self-pay is $299–$449 depending on dose. Compounded tirzepatide through Oak is $199/month flat. Oak typically wins on price; LillyDirect wins on brand assurance.
4. You're paying cash, no insurance. Both Mounjaro and Zepbound retail near $1,070–$1,086 — functionally identical. Cheapest brand path: Zepbound via LillyDirect at $299 (Mounjaro is no longer offered through LillyDirect). Cheapest tirzepatide path overall: compounded through Oak at $199/month.
5. You're on Medicare. Mounjaro for diabetes is typically covered under your Part D plan with standard copays. Zepbound for weight loss is excluded from standard Part D but is covered under the Medicare GLP-1 Bridge at $50/month from July 2026 if you qualify (KwikPen formulation only). Take the free eligibility checker to find out in about a minute.

To run your specific situation against every program automatically, use our free comparison tool — it weighs your insurance type, condition, and state against current pricing across every active telehealth provider, manufacturer program, and Medicare pathway.

Switching Between Mounjaro and Zepbound

Because Mounjaro and Zepbound are the same molecule at the same doses, switching between them is clinically trivial. Same effect, no re-titration needed, no break in treatment. Your prescriber simply writes the prescription for the other brand at your current dose.

The complications are administrative, not clinical:

• Insurance prior authorization may need to be redone. Switching from Mounjaro (diabetes indication) to Zepbound (weight management indication) is a different ICD-10 code, which typically triggers a new PA review.
• Your savings card annual cap resets. If you've already used $1,500 of your $1,950 Mounjaro savings card cap and you switch to Zepbound, the Zepbound card is a separate program with its own annual cap.
• Your pharmacy may not stock both. Smaller pharmacies sometimes only stock one tirzepatide brand. Mail-order pharmacies and major retail chains generally carry both.

The common scenarios for switching: a diabetes patient on Mounjaro who develops a stronger weight-loss focus and wants to access Lilly Cares (Mounjaro isn't on it; Zepbound is); a weight-loss patient on Zepbound who develops diabetes and gets better commercial coverage as Mounjaro; a Medicare-eligible patient switching to Zepbound (KwikPen) to access the Bridge at $50/month.

Frequently Asked Questions

Is Zepbound cheaper than Mounjaro?

For most self-pay patients in 2026, yes — Zepbound is slightly cheaper. Zepbound runs $299/month flat on TrumpRx and $299–$449 (tiered by dose) on LillyDirect. Mounjaro runs $350/month flat on TrumpRx and is no longer offered through LillyDirect. For commercially insured patients, the answer flips: Mounjaro is typically cheaper because ~82% of commercial plans cover it for type 2 diabetes (savings card brings copay to $25/month), versus only ~30–40% of plans covering Zepbound for weight loss.

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide, manufactured by Eli Lilly, at the identical dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). Same active ingredient, identical clinical effect. The differences are FDA-approved indication and brand-specific pricing programs.

Can I switch from Mounjaro to Zepbound?

Yes, with a prescriber's order. Switching is clinically trivial — no re-titration needed. Insurance-wise, the switch may require a new prior authorization since the indication changes (diabetes vs. weight loss). Your manufacturer savings card annual cap also resets when you switch brands.

Which has better insurance coverage, Mounjaro or Zepbound?

Mounjaro has substantially broader commercial insurance coverage — roughly 82% of commercial plans cover it for type 2 diabetes, vs. only 30–40% of plans covering Zepbound for weight management. Medicare Part D and most state Medicaid plans cover Mounjaro for diabetes but largely exclude Zepbound for weight loss. Starting July 1, 2026, however, Zepbound (KwikPen formulation only) is covered under the Medicare GLP-1 Bridge Program at $50/month for qualifying beneficiaries — Mounjaro is not in the Bridge.

How much is Mounjaro without insurance in 2026?

Retail Mounjaro runs approximately $1,070/month. With the savings card "uncovered" rebate (commercial insurance required), net cost lands ~$571/month. Self-pay through TrumpRx is $350/month flat. Mounjaro is no longer available through LillyDirect. Compounded tirzepatide through Oak runs $199/month flat.

How much is Zepbound without insurance in 2026?

Retail Zepbound runs approximately $1,086/month. With the savings card "uncovered" rebate, net cost lands ~$436/month. Self-pay through TrumpRx is $299/month flat. Self-pay through LillyDirect ranges from $299 (2.5 mg) to $449 (7.5 mg+). Compounded tirzepatide through Oak runs $199/month flat.

Is there a generic for Mounjaro or Zepbound?

No. Tirzepatide is patented by Eli Lilly and no generic is available in 2026. The closest substitute is compounded tirzepatide from licensed compounding pharmacies under the FDA's drug-shortage provisions. Compounded products are not FDA-approved like brand-name but contain the same active molecule. Generic tirzepatide is not expected before the late 2030s based on current patent timelines.

Can I get compounded tirzepatide instead?

Yes, through licensed telehealth providers. Verified options include Oak at $199/month flat across all doses. Important caveats: compounded tirzepatide is not FDA-approved like brand Mounjaro and Zepbound, the FDA has issued warnings about some compounded products, and product quality varies by pharmacy. Before signing up, work through our provider legitimacy checklist to confirm the provider operates a licensed telehealth platform with proper compounding-pharmacy fulfillment.

Sources & References

• Eli Lilly — mounjaro.com, zepbound.lilly.com (prescribing information, savings card programs); lillydirect.lilly.com (Zepbound self-pay); lillycares.com (PAP)
• FDA — FDA.gov for Mounjaro and Zepbound prescribing information and approval history
• Medicare — medicare.gov; CMS for the GLP-1 Bridge Program details
• Commercial coverage rates — GoodRx / MMIT formulary analysis (2026 estimates)